Rituximab treatment in patients with refractory inflammatory myopathies

Rheumatology

Volumn 50, Issue 12, 2011, Pages 2206-2213

  Mahler, Elien A M ^a   Blom, Marlies ^a   Voermans, Nicol C ^a   van Engelen, Baziel G M ^a   van Riel, Piet L C M ^a   Vonk, Madelon C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dermatomyositis; Disease activity; Functional status; Muscle strength; Polymyositis; Quality of life; Refractory; Rituximab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CLEMASTINE; CORTICOSTEROID; CREATINE KINASE; CYCLOSPORIN; IMMUNOGLOBULIN; INFLIXIMAB; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYNAMOMETRY; FEVER; FOLLOW UP; GASTROENTERITIS; HEART FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; MUSCLE STRENGTH; MYOSITIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTORY INFLAMMATORY MYOPATHY; RELAPSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; CREATINE KINASE; DERMATOMYOSITIS; DRUG RESISTANCE; FEMALE; HAND STRENGTH; HUMANS; INFUSIONS, INTRAVENOUS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE, SKELETAL; POLYMYOSITIS; QUALITY OF LIFE; RECURRENCE; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82355175356     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker088     Document Type: Article

References (43)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
2. Brouwer R, Hengstman GJ, Vree EW et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
3. Hengstman GJ, Brouwer R, Egberts WT et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69-75.
4. Hengstman GJ, van Venrooij WJ, Vencovsky J, Moutsopoulos HM, van Engelen BG. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis 2000;59: 141-2.
5. Brouwer R, Vree EW, Jongen PH, van Engelen BG, van Venrooij WJ. Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis Rheum 1998;41: 1428-37.
6. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70: 360-74.
7. Miller FW. Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies. J Am Med Assoc 1993;270:1846-9.
8. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279-89.
9. Barbasso Helmers S, Lundberg IE. Idiopathic inflammatory myopathies: diagnosis, treatment, and assessment. Int J Adv Rheumatol 2008;5:114-22.
10. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother 2009;10:1183-90.
11. Cherin P, Herson S, Wechsler B et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991;91:162-8.
12. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6.
13. Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology 2002;41:7-13.
14. Pipitone N, Salvarani C. Established and new treatments of the idiopathic inflammatory myopathies: dermatomyositis and polymyositis. Clin Exp Rheumatol 2007;25: 896-906.
15. Keystone E, Fleischmann R, Emery P et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.
16. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 2007;57:538-42.
17. Tokunaga M, Fujii K, Saito K et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 2005;44:176-82.
18. Greenberg SA, Amato AA. Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 2004;17:359-64.
19. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
20. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-6.
21. Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008;26:887-93.
22. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65:974-5.
23. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005;11:264-6.
24. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-7.
25. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-70.
26. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34:1864-8.
27. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
28. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
29. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
30. Zandbelt MM, Welsing PM, van Gestel AM, van Riel PL. Health assessment questionnaire modifications: is standardisation needed? Ann Rheum Dis 2001;60:841-5.
31. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care 1995;33(Suppl. 4): AS264-79.
32. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
33. Rider LG, Giannini EH, Brunner HI et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50: 2281-90.
34. Alexanderson H, Lundberg IE. Disease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis. Clin Exp Rheumatol 2007;25:S153-8.
35. Miller FW, Rider LG, Chung YL et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
36. Van der Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry 1991;54:244-7.
37. Yamasaki Y, Yamada H, Yamasaki M et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007;46:124-30.
38. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003;32:273-84.
39. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep 2003;5:425-30.
40. Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995;2:1-9.
41. Eisenstein DM, O'Gorman MR, Pachman LM. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997; 24:1830-2.
42. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990;27:343-56.
43. Engel AG, Hohlfeld R, Banker B. The dermatomyositis and inclusion body myositis syndromes. In: Engel AG, Amstrong C, eds. Myology. New York: McGraw-Hill, 1994:1335-83.